Aytu BioPharma reported fourth quarter fiscal 2026 revenue of $16.1 million, a 6.4% increase from the prior year, though results fell significantly short of the $24.52 million consensus estimate. The company achieved a near break-even net loss of less than $0.1 million, an improvement from a $19.8 million loss in the prior-year period, largely aided by a $1.0 million gain in derivative warrant liabilities.
Key Highlights
- EXXUA generated $3.9 million in its first full launch quarter, with total prescriptions increasing 138% sequentially to 3,323.
- ADHD portfolio revenue fell 20.6% to $10.4 million due to the commercial prioritization of EXXUA and generic competition for Adzenys.
- Adjusted EBITDA declined to $0.5 million from $2.0 million year-over-year as the company increased investments in commercialization activities.
- Cash and cash equivalents stood at $26.3 million as of June 30, 2026, down from $31.0 million in the previous year.